Quick Answer
UroGen Pharma Ltd. reported Operating Income Loss of -$124.86 million for the year ending 2025.
- UroGen Pharma Ltd. showed a decrease of -29.0% in Operating Income Loss from 2024 to 2025.
- This data is from UroGen Pharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), UroGen Pharma Ltd.'s Operating Income Loss has declined by 906.1%.
- Historical annual values: Fiscal year 2025: -$124.86 million | Fiscal year 2024: -$96.78 million | Fiscal year 2023: -$65.54 million | Fiscal year 2022: -$79.04 million | Fiscal year 2021: -$92.29 million | Fiscal year 2020: -$126.74 million | Fiscal year 2019: -$109.48 million | Fiscal year 2018: -$77.18 million | Fiscal year 2017: -$19.95 million | Fiscal year 2016: $798.0 thousand | Fiscal year 2015: -$12.41 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: